Drawing for DIPROSONE

USPTO serial 85599657

DIPROSONE

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
KEATING, MICHAEL P
Law office
—

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DIPROSONE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Barbara A. Friedman

BARBARA A. FRIEDMAN EDELL, SHAPIRO & FINNAN, LLC1901 RESEARCH BLVD STE 400ROCKVILLE, MD 20850-6120UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Corticosteroid preparationABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 27, 2012MAB5ABANDONMENT NOTICE MAILED - AFTER PUBLICATION—
Jul 27, 2012ABN5ABANDONMENT - AFTER PUBLICATION—
Jul 24, 2012EXARTEAS EXPRESS ABANDONMENT RECEIVED—
Jul 3, 2012NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 3, 2012PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 13, 2012NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
May 22, 2012CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
May 21, 2012DOCKASSIGNED TO EXAMINER—
Apr 24, 2012NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 20, 2012NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance